Blue Barn Wealth LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Blue Barn Wealth LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 2,625 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of GILD. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $26,000. Tompkins Financial Corp lifted its position in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. Rakuten Securities Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth $33,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $40,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the transaction, the insider now directly owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Down 0.8 %

Gilead Sciences stock traded down $0.54 during mid-day trading on Wednesday, reaching $64.92. The company’s stock had a trading volume of 5,083,375 shares, compared to its average volume of 7,428,300. The business’s 50 day simple moving average is $70.25 and its 200 day simple moving average is $75.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The company has a market capitalization of $80.83 billion, a price-to-earnings ratio of 181.83, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter last year, the firm posted $1.37 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.74%. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several analyst reports. Morgan Stanley dropped their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Mizuho lowered their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Barclays cut their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, Oppenheimer reiterated an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.